EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineering antimicrobial peptides through the design–build–test–learn framework

Yinbiao Xu, Jingbo Xu, Wanting Zhu, Wenhao Zhang, Peizhao Yang, Rui Chen, Xuanzheng Li, Haosheng Lin, Junhao Luo, Yongjie Ma, Kangjia Jiang, Jinyuan Hu

FEMS Microbiology Reviews · 17.11.2026

DOI: 10.1093/femsre/fuag060 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEMS Microbiology Reviews, online erschienen am 17.11.2026. Verfasst von Yinbiao Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Henan University, Kaifeng 475004, China. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rapid emergence of antimicrobial resistance has intensified the need for alternative anti-infective strategies. Antimicrobial peptides (AMPs) offer diverse mechanisms of action, but their translation remains constrained by poor physiological stability, host toxicity, and manufacturing costs. This review examines AMP development within a design–build–test–learn (DBTL) framework that connects computational discovery, peptide production, experimental evaluation, and iterative optimization. Proteome mining and generative artificial intelligence expand the accessible sequence space, while solid-phase synthesis, engineered microbial hosts, and cell-free systems convert selected sequences into testable molecules. Chemical modification and formulation provide complementary routes to improve stability and delivery. Standardized screening and in vivo studies then establish the evidence needed to prioritize candidates and inform subsequent design and production decisions. Throughout this cycle, activity must be optimized together with toxicity, stability, manufacturability, and delivery rather than treated as the sole measure of success. This review discusses applications in medicine, agriculture, food preservation, and biotechnology, and identifies remaining limitations in data quality, assay comparability, scale-up, and translational support. The DBTL framework provides a basis for coordinating these activities, although its practical value depends on experimentally validated feedback and application-specific development criteria.

Schlagwörter

Stichwörter der Autor:innen

Antimicrobial peptides (AMPs)Clinical translationDesign–build–test–learnGenerative AIHigh-throughput screeningSynthetic biology

Autor:innen und Institutionen

  • College of Life Sciences, Henan University, Kaifeng 475004, China.
  • Faculty of Arts and Sciences, Beijing Normal University, Zhuhai 519087, China.
  • Key Laboratory of Cell Proliferation and Regulation Biology of Ministry of Education, Guangdong Zhuhai-Macao Joint Biotech Laboratory, Beijing Normal University, Zhuhai 519087, China.

Zitieren

APA

Xu, Y., Xu, J., Zhu, W., Zhang, W., Yang, P., Chen, R., Li, X., Lin, H., Luo, J., Ma, Y., Jiang, K., & Hu, J. (2026). Engineering antimicrobial peptides through the design–build–test–learn framework. FEMS Microbiology Reviews. https://doi.org/10.1093/femsre/fuag060

Vancouver

Xu Y, Xu J, Zhu W, Zhang W, Yang P, Chen R, et al. Engineering antimicrobial peptides through the design–build–test–learn framework. FEMS Microbiology Reviews. 2026. doi:10.1093/femsre/fuag060

BibTeX
@article{Xu2026,
  author = {Xu, Yinbiao and Xu, Jingbo and Zhu, Wanting and Zhang, Wenhao and Yang, Peizhao and Chen, Rui and Li, Xuanzheng and Lin, Haosheng and Luo, Junhao and Ma, Yongjie and Jiang, Kangjia and Hu, Jinyuan},
  title = {Engineering antimicrobial peptides through the design–build–test–learn framework},
  journal = {FEMS Microbiology Reviews},
  year = {2026},
  doi = {10.1093/femsre/fuag060}
}
Kostenlos starten →